Revolutionary Arthritis Treatment Secures £1.4m Funding for Mesenbio
Mesenbio, a spin-out company from the University of York in the UK, has secured £1.4m in funding for the development of a revolutionary arthritis treatment. The funding round, co-led by DSW Ventures and NG Bio, also received grant funding from Innovate UK. With this financial support, Mesenbio plans to hire three new team members, refine pilot manufacturing processes, conduct pre-clinical studies, and prepare the necessary regulatory documentation for upcoming clinical trials.
Founded by Professor Paul Genever and Dr.
David Kuntin, Mesenbio is building a unique treatment for arthritis that is derived from engineered human stem cells. This cutting-edge therapy initially targets rheumatoid arthritis, a condition that affects nearly half a million individuals in the UK. Rheumatoid arthritis is an autoimmune disease that leads to severe joint pain and inflammation in the hands, knees, elbows, ankles, and wrists. By utilizing nano-sized messengers generated from engineered human stem cells, Mesenbio's treatment not only reduces inflammation but also kick-starts the process of regenerating damaged tissue.
The innovative approach developed by Mesenbio holds great promise in significantly improving the lives of those affected by arthritis. With this recent funding, the company is now well-positioned to advance its research, bringing hope to individuals suffering from this debilitating condition. The progress made by Mesenbio is a testament to the groundbreaking work carried out at the University of York's Biomedical Research Institute, highlighting the invaluable contribution of academic institutions to medical advancements.
They've invested in Mesenbio
Get to know these Healthtech investors
Click here for a full list of 7,526+ startup investors in the UK